
    
      The relapsed and/or refractory AML patients will receive infusions of allogeneic CART-33
      within 1 week after chemotherapy. The re-induction chemotherapy regimen was primarily
      idarubicin and cytarabine, and no graft-versus-host disease (GVHD) prevention was conducted
      pre- and post- therapy.
    
  